ADVFN ADVFN

Hot Features

Icon for alerts 登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
Sanofi (PK)

Sanofi (PK) (SNYNF)

88.35
0.905
(1.03%)
終了 7月13日 5:00AM

Sanofi (PK) (SNYNF) 銘柄情報

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

主要統計と詳細

通貨
88.35
( 1.03% )
買値
83.11
売値
90.63
出来高
276
平均取引量 (3 か月)
US$ 2,435,408
財務取引量
US$ 24,341
88.044 日の範囲 88.35
80.742 52 週間の範囲 106.34
時価総額
企業価値
105.273B
前日終値
87.445
始値
88.044
最終取引時間
VWAP
88.1931
歳入
47.35B
純利益
7.56B
発行済株式数
1,200,220,109
浮動株比率 (%)
90.30%
機関投資家保有比率 (%)
44.32%
配当利回り
(5.35%)
PER
19.01
株価売上高倍率 (PSR)
1.91
1 株当たり利益 (EPS)
6.2
ベータ
0.28

Sanofi (PK) について

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respi... Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine’s AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV’574, for treatment of ulcerative colitis and Crohn’s disease; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France. 詳細を表示

セクター
-
業界
-
ウェブサイト
本社
Paris, France
設立
1994
Sanofi (PK) is listed in the sector of the その他OTC with ticker SNYNF. The last closing price for Sanofi (PK) was US$87.45. Over the last year, Sanofi (PK) shares have traded in a share price range of US$ 80.742 to US$ 106.34.

Sanofi (PK) currently has 1,200,220,109 shares in issue. The market capitalisation of Sanofi (PK) is US$106.04 billion. Sanofi (PK) has a price to earnings ratio (PE ratio) of 19.01.

SNYNF 最新ニュース

期間 †前日比前日比 %始値高値安値平均出来高VWAP
14.65.4925373134383.7588.78683.17281384.66635071CS
4-0.2-0.22586109542688.5589.5380.742978783.79516238CS
12-7.6-7.9207920792195.9596.4180.742618287.24299174CS
26-9.938-10.111102067498.28898.28880.7422270894.49945041CS
52-10.354-10.489949748798.704106.3480.7423067195.08352452CS
156-17.884-16.8345350829106.234122.02880.7422163997.05663909CS
260-17.94-16.8783516794106.29122.02873.312531493.84478491CS

SNYNF - Frequently Asked Questions (FAQ)

What is the current Sanofi (PK) share price?
The current share price of Sanofi (PK) is US$ 88.35
How many Sanofi (PK) shares are in issue?
Sanofi (PK) has 1,200,220,109 shares in issue
What is the market cap of Sanofi (PK)?
The market capitalisation of Sanofi (PK) is USD 106.04B
What is the 1 year trading range for Sanofi (PK) share price?
Sanofi (PK) has traded in the range of US$ 80.742 to US$ 106.34 during the past year
What is the PE ratio of Sanofi (PK)?
The price to earnings ratio of Sanofi (PK) is 19.01
What is the cash to sales ratio of Sanofi (PK)?
The cash to sales ratio of Sanofi (PK) is 1.91
What is the registered address of Sanofi (PK)?
The registered address for Sanofi (PK) is 46, avenue de la Grande ArmEe, Paris, Ile-de-France, 75017
What is the Sanofi (PK) website address?
The website address for Sanofi (PK) is www.sanofi.com

SNYNF 取引

さらに

取引は遅延しています

リアルタイムの取引を取得するには、アカウントをアップグレードしてください

リアルタイムにアップグレード